Teplizumab Eligibility And Course

---
name: teplizumab-eligibility-and-course
description: Decide whether a person with confirmed early-stage type 1 diabetes qualifies for teplizumab (Tzield) — the anti-CD3 disease-modifying antibody that delays progression from Stage 2 to Stage 3 T1D — and outline the 14-day intravenous course, expected benefit, regulatory status, and pre-treatment work-up. Use when a clinician asks whether a patient with early T1D qualifies for teplizumab, indication for Tzield, Stage 2 T1D what treatment is available, how to delay onset of T1D, is teplizumab available for a child with autoantibodies, HbA1c 6.0% and GAD-positive is this teplizumab territory, or is planning the disease-modifying treatment pathway for early-stage T1D. Grounded in Hussain et al 2026 (Diabetes, Obesity and Metabolism, IDF Europe consensus, DOI 10.1111/dom.70569) and the underlying TN-10 trial data (Herold et al, NEJM 2019 and long-term extension).
---

# Teplizumab (Tzield) — Eligibility & Course

Assess whether a person with early-stage T1D qualifies for the anti-CD3 monoclonal antibody teplizumab, and plan the 14-day IV course. Teplizumab is the first and currently only approved disease-modifying therapy that delays clinical (Stage 3) T1D.

---

## Step 1 — Confirm the indication is Stage 2 T1D

Teplizumab is approved **only for Stage 2 T1D**. Verify:

| Criterion | Requirement |
|---|---|
| **Autoantibodies** | **≥2 confirmed islet autoantibodies** (from GAD65, IAA, IA2, ZnT8), each positive on a second sample using 2 independent methods |
| **Glycaemia** | **Dysglycaemia below ADA diagnostic thresholds** — Stage 2a (FPG 5.6–6.9 mmol/L / 100–124 mg/dL, or 2h OGTT 7.8–11.0 mmol/L / 140–198 mg/dL, or HbA1c 39–47 mmol/mol / 5.7–6.4%) or Stage 2b (as 2a PLUS CGM time >7.8 mmol/L / >140 mg/dL of >10%) |
| **Symptoms** | **Asymptomatic** — no osmotic symptoms (polyuria, polydipsia, weight loss), no DKA presentation |
| **Age** | Approved in ages 8 years and above (FDA). Local regulator may vary — check the label |

**If the person is at Stage 1** (autoantibody positive but normoglycaemic) → **NOT eligible** at this time. Continue monitoring; retest glycaemia at each visit to detect progression to Stage 2.

**If the person is at Stage 3** (already meets ADA diagnostic criteria for diabetes) → **NOT the approved indication** for teplizumab. At Stage 3, standard insulin therapy applies; the disease-modifying effect is smaller and outside the current approved label. Trials continue in Stage 3 with other agents (abatacept, ATG, golimumab, baricitinib, verapamil).

---

## Step 2 — Confirm regulatory availability where you practise

| Region | Status |
|---|---|
| **USA (FDA)** | Approved November 2022 for Stage 2 T1D in patients ≥8 years |
| **Canada (Health Canada)** | Approved |
| **UK (MHRA)** | Approved |
| **EU (EMA)** | Approved; accepted for FDA National Priority Voucher pilot program |
| **India (CDSCO)** | Not yet approved as of 2026 — access is by named-patient / compassionate use / import route only. Verify with the manufacturer or local regulatory contact before promising availability |
| **Other regions** | Check the local regulator; approval status is changing quickly |

**Practical implication:** even where the drug is approved, cost and access remain limiting. Discuss availability, price, insurance / public-payer coverage, and drug-import logistics before raising expectations with the family.

---

## Step 3 — Assess for contraindications and complications risk

Before infusion, check:

- **Active or recent infection** — teplizumab causes transient lymphopaenia; defer during active infection
- **History of severe hypersensitivity to teplizumab** (contraindication)
- **Pregnancy / breastfeeding** — insufficient safety data; avoid unless benefit clearly outweighs
- **Recent live vaccine** — hold live vaccines from 8 weeks before through 52 weeks after teplizumab; inactivated vaccines from 2 weeks before through the treatment course. Update the vaccination schedule proactively
- **Pre-existing chronic viral infection** (EBV, CMV, HIV, HBV, HCV) — active or reactivation risk; specialist input
- **Baseline blood tests:**
  - CBC with differential (baseline lymphocyte count)
  - Liver function tests (LFTs)
  - EBV serology if not previously documented
  - Consider CMV, HBV, HCV per local protocol
  - Pregnancy test in females of childbearing potential

---

## Step 4 — The 14-day intravenous course

**Standard regimen:** teplizumab **once daily IV infusion for 14 consecutive days.**

- **Dosing:** weight-based per label — starts at a lower dose day 1 (65 μg/m²), escalates through day 5 (250 μg/m²) then maintenance to day 14
- **Route:** intravenous over approximately 30 minutes; monitoring during and after infusion
- **Premedication** (per label to reduce infusion reactions):
  - Antipyretic (paracetamol/acetaminophen)
  - Antihistamine
  - Antiemetic
- **Monitoring during infusion:** vital signs, infusion-reaction watch, hypersensitivity
- **Monitoring post-course:**
  - CBC weekly during and shortly after the course (lymphopaenia expected; usually recovers)
  - LFTs during and after the course
  - Watch for cytokine release syndrome, serum sickness, rash, headache

---

## Step 5 — Set expectations for benefit

**From TN-10 trial data (Herold et al):**

- **Median time to Stage 3 T1D:** **48.4 months** (teplizumab) vs **24.4 months** (placebo). Roughly a **2-year delay**
- **Hazard ratio 0.41** for progression to Stage 3
- **Diagnosis of Stage 3 by end of primary follow-up:** 43% (teplizumab) vs 72% (placebo)

**Extended follow-up (median 923 days):**

- Median time to Stage 3: **59.6 months** (teplizumab) vs **27.1 months** (placebo)
- **50% of teplizumab-treated remained diabetes-free** vs 22% of placebo (HR 0.46)
- **Improved β-cell function** — C-peptide preserved on teplizumab, declined in placebo
- Improvement in C-peptide correlated with reduced T-cell secretion of IFNγ and TNFα (mechanistic support)

**Communicate honestly to the family:**

- Teplizumab **delays** Stage 3 T1D — it does not permanently prevent it (in most people)
- On average about 2 years of extra insulin-free life
- Some people benefit more, some less; individual response varies
- Preservation of β-cell function may translate to easier T1D management even after progression (less brittle glycaemia, lower HbA1c, potentially fewer complications long-term)
- No proven long-term reduction in microvascular / macrovascular complications yet — data will accrue over decades

---

## Step 6 — Plan post-course monitoring

After the 14-day course:

- **Continue routine early-stage T1D monitoring** — regular glucose monitoring (CGM), HbA1c, education, psychological support
- **Symptom surveillance** — the person is still at risk of progression; osmotic symptoms warrant urgent evaluation
- **Retest CBC/LFTs** per label
- **Watch for infusion-related delayed effects** — serum sickness, rash, cytokine effects can appear days after
- **Vaccination catch-up** — resume inactivated vaccines after the specified interval, live vaccines only after 52 weeks post-course
- **Second course** — a retreatment course is not currently a standard indication in the approved label; investigational

---

## Guardrails

- **Teplizumab is a specialist infusion — not something to initiate outside a centre with disease-modifying-therapy infrastructure** for autoimmune diabetes. Refer to a T1D specialist / research centre if your unit lacks the infrastructure
- **Do not offer teplizumab in Stage 1** — outside the approved indication, evidence is limited and the risk/benefit is unfavourable
- **Do not offer teplizumab after Stage 3** — outside the approved indication, insulin is the standard
- **A single unconfirmed autoantibody positive is NOT an indication** — verify with the mandatory two-sample two-method confirmation first (see `t1d-islet-autoantibody-screening-confirmation`)
- **Screen for pre-existing infection carefully** — post-teplizumab lymphopaenia can reactivate latent viral infections. EBV in particular deserves attention
- **Manage vaccine timing PROACTIVELY** — a child scheduled for live MMR / varicella boosters, or an adolescent scheduled for HPV, needs their schedule reviewed against the 8-weeks-before / 52-weeks-after live-vaccine rule. Missed windows delay the course or delay the vaccines
- **Communicate the ~2-year delay honestly** — the drug is not a cure. Families may hear "delays T1D" and expect prevention; use the actual numbers (48.4 vs 24.4 months; 50% still diabetes-free at long-term follow-up vs 22%)
- **Cost, access, and geography matter** — do not raise expectations before confirming the drug is actually obtainable and affordable in the person's country / insurance / import pathway
- **Psychosocial support is not optional** — the Stage 2 diagnosis + a 14-day IV course is a significant intervention on a still-asymptomatic child. Anxiety, family stress, school disruption, and adherence issues are common. Involve a psychologist / diabetes educator from the start
- **Monitor for delayed adverse events** (cytokine release, serum sickness, prolonged lymphopaenia) — not all reactions happen during infusion
- **Document the batch number and any concomitant medications** in the record — biological product traceability

---

## Related MD2SKILL skills

- `t1d-staging-classifier` — must classify to Stage 2 before considering teplizumab
- `t1d-islet-autoantibody-screening-confirmation` — the confirmed-antibody status is a prerequisite
- `diabetes-vaccination-checker` — coordinate vaccine schedule around the live-vaccine window

---

## Source

Hussain S, Tree T, Mathieu C, Klupa T, Tuomaala A-K, de Wit M, Kordonouri O, Braune K, Pall J, Castano L, Besser REJ, Galhardo J, Ulivi F, Bosi E, Bogdanovic U, Alabert C, Battelino T. **An international consensus on screening and monitoring early-stage type 1 diabetes: A roadmap to European implementation.** *Diabetes, Obesity and Metabolism.* 2026;28:3535–3556. DOI: 10.1111/dom.70569. Open-access under Creative Commons Attribution (CC-BY). Section 4 "Potential for immunotherapy of early-stage T1D".

Underlying trial: Herold KC, Bundy BN, Long SA, et al. **An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes.** *N Engl J Med* 2019;381:603-613. TN-10 study; long-term follow-up published subsequently.